Gene activation therapy: From the BLV model to HAM/TSP patients

Frontiers in Bioscience - Scholar

Volumn 1 S, Issue 1, 2009, Pages 205-215

  Lezin, Agnes ^a   Olindo, Stephane ^a   Belrose, Gildas ^a   Signate, Aissatou ^a   Cesaire, Raymond ^a   Smadja, Didier ^a   Macallan, Derek ^b   Asquith, Becca ^c   Bangham, Charles ^c   Bouzar, Amel ^d   Gillet, Nicolas ^c   Defoiche, Julien ^d   Florins, Arnaud ^d   Verlaeten, Olivier ^d   Burny, Arsene ^d   Willems, Luc ^d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

BLV; Cell turnover; HDAC inhibitor; HTLV; Immune response; Leukaemia; Review

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; BOVINE LEUKEMIA VIRUS; GENE EXPRESSION; GENE THERAPY; GENETICS; HUMAN; PHYSIOLOGY; REVIEW; SHEEP; TROPICAL SPASTIC PARAPARESIS;

ANIMALS; GENE EXPRESSION; GENE THERAPY; HUMANS; LEUKEMIA VIRUS, BOVINE; MODELS, BIOLOGICAL; PARAPARESIS, TROPICAL SPASTIC; SHEEP;

EID: 77954483324     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/e20     Document Type: Article

References (81)

1. N. Gillet, A. Florins, M. Boxus, C. Burteau, A. Nigro, F. Vandermeers, H. Balon, A. B. Bouzar, J. Defoiche, A. Burny, M. Reichert, R. Kettmann, and L. Willems, Mechanisms of leukemogenesis induced by bovine leukemia virus: prospect. for novel anti-retroviral therapies in human, Retrovirology 4:18 (2007)
2. S. Dube, S. Bachman, T. Spicer, J. Love, D. Choi, E. Esteban, J. F. Ferrer, and B. J. Poiesz, Degenerate and specific PCR assays for the detection of bovine leukaemia virus and primate T cell leukaemia/lymphoma virus pol DNA and RNA: phylogeneti. comparisons of amplified sequences from cattle and primates from around the world, J. Gen. Virol. 78(Pt 6):1389 (1997)
3. M. Onuma, K. Tsukiyama, K. Ohya, Y. Morishima, and R. Ohno, Detection of cross-reactive antibody to BLV p24 in sera of human patients infected with HTLV, Microbiol. Immunol. 31:131 (1987)
4. B. K. Felber, D. Derse, A. Athanassopoulos, M. Campbell, and G. N. Pavlakis, Cross-activation of the Rex proteins of HTLV-I and BLV and of the Rev protein of HIV-1 and nonreciprocal interactions with their RNA responsive elements, New Biol. 1:318 (1989)
5. L. Lefebvre, A. Vanderplasschen, V. Ciminale, H. Heremans, O. Dangoisse, J. C. Jauniaux, J. F. Toussaint, V. Zelnik, A. Burny, R. Kettmann, and L. Willems, Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13 (II) accessory proteins interact with farnesyl pyrophosphate synthetase, Journal of Virology 76:1400 (2002)
6. R. Kettmann, D. Portetelle, M. Mammerickx, Y. Cleuter, D. Dekegel, M. Galoux, J. Ghysdael, A. Burny, and H. Chantrenne, Bovine leukemia virus: a. exogenous RNA oncogenic virus, Proc. Natl. Acad. Sci. U. S. A 73:1014 (1976)
7. I. Leclercq, F. Mortreux, M. Cavrois, A. Leroy, A. Gessain, S. Wain-Hobson, and E. Wattel, Host sequences flanking the human T-cell leukemia virus type 1 provirus in vivo, J. Virol. 74:2305 (2000)
8. T. Igakura, J. C. Stinchcombe, P. K. Goon, G. P. Taylor, J. N. Weber, G. M. Griffiths, Y. Tanaka, M. Osame, and C. R. Bangham, Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton, Science 299:1713 (2003)
9. K. Inabe, K. Ikuta, and Y. Aida, Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus, Virology 245:53 (1998)
10. D. Derse, J. Mikovits, M. Polianova, B. K. Felber, and F. Ruscetti, Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells, J. Virol. 69:1907 (1995)
11. D. Derse, B. Crise, Y. Li, G. Princler, N. Lum, C. Stewart, C. F. McGrath, S. H. Hughes, D. J. Munroe, and X. Wu, Human T-cell leukemia virus type 1 integration target sites in the human genome: compariso. with those of other retroviruses, J. Virol. 81:6731 (2007)
12. R. Kettmann, J. Deschamps, Y. Cleuter, D. Couez, A. Burny, and G. Marbaix, Leukemogenesis by bovine leukemia virus: provira. DNA integration and lack of RNA expression of viral long terminal repeat and 3' proximate cellular sequences, Proc. Natl. Acad. Sci. U. S. A 79:2465 (1982)
13. K. Doi, X. Wu, Y. Taniguchi, J. Yasunaga, Y. Satou, A. Okayama, K. Nosaka, and M. Matsuoka, Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states, Blood 106:1048 (2005)
14. F. Mortreux, I. Leclercq, A. S. Gabet, A. Leroy, E. Westhof, A. Gessain, S. Wain-Hobson, and E. Wattel, Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo, J. Natl. Cancer Inst. 93:367 (2001)
15. V. Moules, C. Pomier, D. Sibon, A. S. Gabet, M. Reichert, P. Kerkhofs, L. Willems, F. Mortreux, and E. Wattel, Fate of premalignant clones during the asymptomatic phase preceding lymphoid malignancy, Cancer Res. 65:1234 (2005)
16. T. Amagasaki, S. Momita, J. Suzuyama, Y. Yamada, S. Ikeda, K. Kinoshita, and M. Ichimaru, Detection of adult T-cell leukemia-associated antigen in T-cell malignancies in the Nagasaki district of Japan, Cancer 54:2074 (1984)
17. D. M. Lagarias and K. Radke, Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections, J. Virol. 63:2099 (1989)
18. E. Adam, P. Kerkhofs, M. Mammerickx, A. Burny, R. Kettman, and L. Willems, The CREB, ATF-1, and ATF-2 transcription factors from bovine leukemia virus-infected B lymphocytes activate viral expression, J. Virol. 70:1990 (1996)
19. E. Hanon, R. E. Asquith, G. P. Taylor, Y. Tanaka, J. N. Weber, and C. R. Bangham, High frequency of viral protein expression in human T cell lymphotropic virus type 1-infected peripheral blood mononuclear cells, AIDS Res. Hum. Retroviruses 16:1711 (2000)
20. E. Wattel, M. Cavrois, A. Gessain, and S. WainHobson, Clonal expansion of infected cells: A wa. of life for HTLV-I, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13:S92 (1996)
21. E. Hanon, J. C. Stinchcombe, M. Saito, B. E. Asquith, G. P. Taylor, Y. Tanaka, J. N. Weber, G. M. Griffiths, and C. R. Bangham, Fratricide among CD8 (+) T lymphocytes naturally infected with human T cell lymphotropic virus type I, Immunity 13:657 (2000)
22. P. Lundberg and G. A. Splitter, gammadelta (+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host, J. Virol. 74:8299 (2000)
23. D. Portetelle, C. Bruck, M. Mammerickx, and A. Burny, In animals infected by bovine leukemia virus (BLV) antibodies to envelope glycoprotein gp51 are directed against the carbohydrate moiety, Virology 105:223 (1980)
24. B. Asquith, Y. Zhang, A. J. Mosley, C. M.de Lara, D. L. Wallace, A. Worth, L. Kaftantzi, K. Meekings, G. E. Griffin, Y. Tanaka, D. F. Tough, P. C. Beverley, G. P. Taylor, D. C. Macallan, and C. R. Bangham, In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection, Proc. Natl. Acad. Sci. U. S A 104:8035 (2007)
25. C. Debacq, B. Asquith, P. Kerkhofs, D. Portetelle, A. Burny, R. Kettmann, and L. Willems, Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep, Proc. Natl. Acad. Sci. U. S A 99:10048 (2002)
26. S. A. Hill, M. Shuh, and D. Derse, Comparisons of defective HTLV-I proviruses predict the mode of origin and coding potential of internally deleted genomes, Virology 263:273 (1999)
27. M. Miyazaki, J. Yasunaga, Y. Taniguchi, S. Tamiya, T. Nakahata, and M. Matsuoka, Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5' long terminal repeat during oncogenesis, J. Virol. 81:5714 (2007)
28. M. A. Beilke, D. R. In, M. Gravell, R. S. Hamilton, C. A. Mora, M. Leon-Monzon, P. E. Rodgers-Johnson, D. C. Gajdusek, C. J. Gibbs, Jr., and V. Zaninovic, In situ hybridization detection of HTLV-I RNA in peripheral blood mononuclear cells of TSP/HAM patients and their spouses, J. Med. Virol. 33:64 (1991)
29. A. Gessain, F. Saal, M. L. Giron, J. Lasneret, S. Lagaye, O. Gout, G. De The, F. Sigaux, and J. Peries, Cell surface phenotype and human T lymphotropic virus type 1 antigen expression in 12 T cell lines derived from peripheral blood and cerebrospinal fluid of West Indian, Guyanese and African patients with tropical spastic paraparesis, J. Gen. Virol. 71(Pt 2):333 (1990)
30. A. Gessain, A. Louie, O. Gout, R. C. Gallo, and G. Franchini, Human T-cell leukemia-lymphoma virus type I (HTLV-I) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I- associated myelopathy, J. Virol. 65:1628 (1991)
31. Y. Morishima, K. Ohya, R. Ueda, and T. Fukuda, Detection of adult T-cell leukemia virus (ATLV) bearing lymphocytes in concentrated red blood cells derived from ATL associated antibody (ATLA-Ab) positive donors, Vox Sang. 50:212 (1986)
32. Y. Ohtsuki, I. Miyoshi, H. Taguchi, K. Takahashi, and T. Akagi, Ultrastructural study of type C virus particles in phytohemagglutinin-stimulated lymphocytes from healthy adults seropositive to adult T-cell leukemia-associated antigens, Acta Pathol. Jpn. 34:1277 (1984)
33. T. Tochikura, M. Iwahashi, T. Matsumoto, Y. Koyanagi, Y. Hinuma, and N. Yamamoto, Effect of human serum anti-HTLV antibodies on viral antigen induction in vitro cultured peripheral lymphocytes from adult T-cell leukemia patients and healthy virus carriers, Int. J. Cancer 36:1 (1985)
34. P. Kerkhofs, E. Adam, L. Droogmans, D. Portetelle, M. Mammerickx, A. Burny, R. Kettmann, and L. Willems, Cellular pathways involved in the ex vivo expression of bovine leukemia virus, J. Virol. 70:2170 (1996)
35. M. A. Powers and K. Radke, Activation of bovine leukemia virus transcription in lymphocytes from infected sheep: rapi. transition through early to late gene expression, J. Virol. 66:4769 (1992)
36. S. Daenke, A. G. Kermode, S. E. Hall, G. Taylor, J. Weber, S. Nightingale, and C. R. Bangham, High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis, Virology 217:139 (1996)
37. M. Kannagi, H. Shida, H. Igarashi, K. Kuruma, H. Murai, Y. Aono, I. Maruyama, M. Osame, T. Hattori, H. Inoko, and., Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells, J. Virol. 66:2928 (1992)
38. S. Koenig, R. M. Woods, Y. A. Brewah, A. J. Newell, G. M. Jones, E. Boone, J. W. Adelsberger, M. W. Baseler, S. M. Robinson, and S. Jacobson, Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease, J. Immunol. 151:3874 (1993)
39. A. Florins, N. Gillet, B. Asquith, M. Boxus, C. Burteau, J. C. Twizere, P. Urbain, F. Vandermeers, C. Debacq, M. T. Sanchez-Alcaraz, I. Schwartz-Cornil, P. Kerkhofs, G. Jean, A. Thewis, J. Hay, F. Mortreux, E. Wattel, M. Reichert, A. Burny, R. Kettmann, C. Bangham, and L. Willems, Cell dynamics and immune response to BLV infection: a unifyin. model, Front Biosci. 12:1520 (2007)
40. P. Kerkhofs, H. Heremans, A. Burny, R. Kettmann, and L. Willems, In vitro and in vivo oncogenic potential of bovine leukemia virus G4 protein, J. Virol. 72:2554 (1998)
41. M. Nerenberg, S. H. Hinrichs, R. K. Reynolds, G. Khoury, and G. Jay, The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice, Science 237:1324 (1987)
42. Y. Satou, J. Yasunaga, M. Yoshida, and M. Matsuoka, HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells, Proc. Natl. Acad. Sci. U. S A 103:720 (2006)
43. L. Willems, H. Heremans, G. Chen, D. Portetelle, A. Billiau, A. Burny, and R. Kettmann, Cooperation between bovine leukaemia virus transactivator protein and Ha-ras oncogene product in cellular transformation, EMBO J. 9:1577 (1990)
44. L. Llames, J. Goyache, A. Domenech, A. V. Montana, G. Suarez, and E. Gomez-Lucia, Cellular distribution of bovine leukemia virus proteins gp51SU, Pr72 (env), and Pr66 (gag-pro) in persistently infected cells, Virus Res. 79:47 (2001)
45. A. Achachi, A. Florins, N. Gillet, C. Debacq, P. Urbain, G. M. Foutsop, F. Vandermeers, A. Jasik, M. Reichert, P. Kerkhofs, L. Lagneaux, A. Burny, R. Kettmann, and L. Willems, Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo, Proc. Natl. Acad. Sci. U. S. A 102:10309 (2005)
46. K. Kamoi, K. Yamamoto, A. Misawa, A. Miyake, T. Ishida, Y. Tanaka, M. Mochizuki, and T. Watanabe, SUV39H1 interacts with HTLV-1 Tax and abrogates Tax transactivation of HTLV-1 LTR, Retrovirology 3:5 (2006)
47. Y. Taniguchi, K. Nosaka, J. Yasunaga, M. Maeda, N. Mueller, A. Okayama, and M. Matsuoka, Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms, Retrovirology 2:64 (2005)
48. G. Gaudray, F. Gachon, J. Basbous, M. Biard-Piechaczyk, C. Devaux, and J. M. Mesnard, The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription, J. Virol. 76:12813 (2002)
49. P. Hivin, J. Basbous, F. Raymond, D. Henaff, C. Arpin-Andre, V. Robert-Hebmann, B. Barbeau, and J. M. Mesnard, The HBZ-SP1 isoform of human T-cell leukemia virus type I represses JunB activity by sequestration into nuclear bodies, Retrovirology 4:14 (2007)
50. J. M. Johnson, C. Nicot, J. Fullen, V. Ciminale, L. Casareto, J. C. Mulloy, S. Jacobson, and G. Franchini, Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12 (I) protein, J. Virol. 75:6086 (2001)
51. R. A. Blaheta, H. Nau, M. Michaelis, and J. Cinatl, Valproate and valproate-analogues: Poten. tools to fight against cancer, Current Medicinal Chemistry 9:1417 (2002)
52. M. Gottlicher, S. Minucci, P. Zhu, O. H. Kramer, A. Schimpf, S. Giavara, J. P. Sleeman, C. F. Lo, C. Nervi, P. G. Pelicci, and T. Heinzel, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, EMBO J. 20:6969 (2001)
53. A. Bazarbachi, D. Ghez, Y. Lepelletier, R. Nasr, H.de The, M. E. El Sabban, and O. Hermine, New therapeutic approaches for adult T-cell leukaemia, Lancet Oncol. 5:664 (2004)
54. O. Hermine, H. Dombret, J. Poupon, B. Arnulf, F. Lefrere, P. Rousselot, G. Damaj, R. Delarue, J. P. Fermand, J. C. Brouet, L. Degos, B. Varet, H.de The, and A. Bazarbachi, Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma, Hematol J. 5:130 (2004)
55. H. Tamaki and M. Matsuoka, Donor-derived T-cell leukemia after bone marrow transplantation, N. Engl. J. Med. 354:1758 (2006)
56. S. Olindo, P. Cabre, A. Lezin, H. Merle, M. Saint-Vil, A. Signate, M. Bonnan, A. Chalon, L. Magnani, R. Cesaire, and D. Smadja, Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-yea. follow-up study, Arch. Neurol. 63:1560 (2006)
57. M. Nakagawa, K. Nakahara, Y. Maruyama, M. Kawabata, I. Higuchi, H. Kubota, S. Izumo, K. Arimura, and M. Osame, Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis, Journal of Neurovirology 2:345 (1996)
58. U. Oh, Y. Yamano, C. A. Mora, J. Ohayon, F. Bagnato, J. A. Butman, J. Dambrosia, T. P. Leist, H. McFarland, and S. Jacobson, Interferon-beta 1a therapy in human T-lymphotropic virus type I-associated neurologic disease, Annals of Neurology 57:526 (2005)
59. M. Saito, M. Nakagawa, S. Kaseda, T. Matsuzaki, M. Jonosono, N. Eiraku, R. Kubota, N. Takenouchi, M. Nagai, Y. Furukawa, K. Usuku, S. Izumo, and M. Osame, Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis, Journal of Infectious Diseases 189:29 (2004)
60. M. Ikegami, F. Umehara, N. Ikegami, R. Maekawa, and M. Osame, Selective matrix metalloproteinase inhibitor, N-biphenyl sulfonyl phenylalanine hydroxamic acid, inhibits the migration of CD4+ T lymphocytes in patients with HTLV-I-associated myelopathy, J. Neuroimmunol. 127:134 (2002)
61. A. Machuca and V. Soriano, In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs, Journal of Acquired Immune Deficiency Syndromes 24:189 (2000)
62. W. A. Sheremata, D. Benedict, D. C. Squilacote, A. Sazant, and E. Defreitas, High-Dose Zidovudine Induction in Htlv-I-Associated Myelopathy - Safety and Possible Efficacy, Neurology 43:2125 (1993)
63. G. P. Taylor, S. E. Hall, S. Navarrete, C. A. Michie, R. Davis, A. D. Witkover, M. Rossor, M. A. Nowak, P. Rudge, E. Matutes, C. R. M. Bangham, and J. N. Weber, Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy, J. Virol. 73:10289 (1999)
64. A. Lezin, N. Gillet, S. Olindo, A. Signate, N. Grandvaux, O. Verlaeten, G. Belrose, B. M.de Carvalho, J. Hiscott, B. Asquith, A. Burny, D. Smadja, R. Cesaire, and L. Willems, Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients, Blood 110:3722 (2007)
65. T. Matsuzaki, M. Nakagawa, M. Nagai, K. Usuku, I. Higuchi, K. Arimura, H. Kubota, S. Izumo, S. Akiba, and M. Osame, HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: Analysi. of 239 HAM/TSP patients including 64 patients followed up for 10 years, Journal of Neurovirology 7:228 (2001)
66. M. Nagai, K. Usuku, W. Matsumoto, D. Kodama, N. Takenouchi, T. Moritoyo, S. Hashiguchi, M. Ichinose, C. R. Bangham, S. Izumo, and M. Osame, Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: hig. proviral load strongly predisposes to HAM/TSP, J. Neurovirol. 4:586 (1998)
67. N. Takenouchi, Y. Yamano, K. Usuku, M. Osame, and S. Izumo, Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, Journal of Neurovirology 9:29 (2003)
68. K. J. Jeffery, K. Usuku, S. E. Hall, W. Matsumoto, G. P. Taylor, J. Procter, M. Bunce, G. S. Ogg, K. I. Welsh, J. N. Weber, A. L. Lloyd, M. A. Nowak, M. Nagai, D. Kodama, S. Izumo, M. Osame, and C. R. Bangham, HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy, Proc. Natl. Acad. Sci. U. S A 96:3848 (1999)
69. K. J. Jeffery, A. A. Siddiqui, M. Bunce, A. L. Lloyd, A. M. Vine, A. D. Witkover, S. Izumo, K. Usuku, K. I. Welsh, M. Osame, and C. R. Bangham, The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection, J. Immunol. 165:7278 (2000)
70. C. R. M. Bangham and M. Osame, Cellular immune response to HTLV-1, Oncogene 24:6035 (2005)
71. A. J. Mosley, K. N. Meekings, C. McCarthy, D. Shepherd, V. Cerundolo, R. Mazitschek, Y. Tanaka, G. P. Taylor, and C. R. Bangham, Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection, Blood 108:3801 (2006)
72. S. Jacobson, Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease, Journal of Infectious Diseases 186:S187 (2002)
73. M. Osame, R. Janssen, H. Kubota, H. Nishitani, A. Igata, S. Nagataki, M. Mori, I. Goto, H. Shimabukuro, R. Khabbaz, and J. Kaplan, Nationwide Survey of Htlv-I Associated Myelopathy in Japan - Association with Blood-Transfusion, Annals of Neurology 28:50 (1990)
74. D. Hinze-Selch, Infection, treatment and immune response in patients with bipolar disorder versus patients with major depression, schizophrenia or healthy controls, Bipolar. Disord. 4 Suppl 1:81 (2002)
75. G. Singh, P. H. Driever, and J. W. Sander, Cancer risk in people with epilepsy: th. role of antiepileptic drugs, Brain 128:7 (2005)
76. D. Miller, Multiple sclerosis: ne. insights and therapeutic progress, Lancet Neurol. 6:5 (2007)
77. R. M. Ransohoff, Natalizumab for multiple sclerosis, N. Engl. J. Med. 356:2622 (2007)
78. S. Dhawan, B. S. Weeks, F. Abbasi, H. R. Gralnick, A. L. Notkins, M. E. Klotman, K. M. Yamada, and P. E. Klotman, Increased expression of alpha 4 beta 1 and alpha 5 beta 1 integrins on HTLV-I-infected lymphocytes, Virology 197:778 (1993)
79. S. Camelo, A. H. Iglesias, D. Hwang, B. Due, H. Ryu, K. Smith, S. G. Gray, J. Imitola, G. Duran, B. Assaf, B. Langley, S. J. Khoury, G. Stephanopoulos, U. De Girolami, R. R. Ratan, R. J. Ferrante, and F. Dangond, Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis, Journal of Neuroimmunology 164:10 (2005)
80. J. D. Sweatt, Behavioural neuroscience: Dow. memory lane, Nature 447:151 (2007)
81. S. Mi, B. Hu, K. Hahm, Y. Luo, E. Sai Kam Hui, Q. Yuan, W. Wong, L. Wang, H. Su, T. Chu, J. Guo, W. Zhang, K. So, B. Pepinsky, Z. Shao, C. Graff, E. Garber, V. Jung, E. Xuekui, and W. Wu, LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis, Nature Medicine 13:1228 (2007)